|
|
Article: Mithridion Announces Progress With Drugs for Alzheimer's Disease and Schizophrenia.
- Article from:
- PR Newswire
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New Product Options in Development, plus Evidence of Disease-Modifying Potential CEO To Present at the 7th Annual MidAmerica Healthcare Venture Forum
MADISON, Wis., Nov 12 /PRNewswire/ -- Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia. New product options have been developed for MCD-386, a clinical-stage drug candidate with "first-in-class" potential for improving memory and cognition in AD, improving cognition in schizophrenia, and for disease-modifying ...